Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product

SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ( “Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower dose version (0.15mg) of Symjepi for...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news